Two cases of concomitant diffuse large B‐cell lymphoma and myelodysplastic syndrome
Massimo Dozzo,F. Zaja,S. Volpetti,Marianna Chiozzotto,S. Puglisi,Maddalena Mazzucco,Giulia Perali,R. Fanin
DOI: https://doi.org/10.1002/ajh.23783
2014-10-01
Abstract:A 64-year-old gentleman was diagnosed in 2011 with myelodisplastic syndrome (MDS)-type refractory cytopenia with monolinear dysplasia (thrombocytopenia), according to the World Health Organization (WHO) classification, International Prognostic Scoring System (IPSS) low risk [1], and was managed only with an observational program. In February 2013, he started complaining of left axillary and supraclavicular adenopathies, together with abdominal pain, abundant night sweats, and weight loss. A supraclavicular lymphnode biopsy performed in March 2013 led to the diagnosis of diffuse large B-cell lymphoma (DLBCL), stage III B [Ann Arbor, International Prognostic Index (IPI) low-intermediate]. Bone marrow aspirate and biopsy performed at the time of DLBCL staging revealed the picture of a multilineage dysplasia with blast excess (Refractory anemia with excess of blast (RAEB) type 2 according to the WHO classification), with normal cytogenetic analysis (46 XY) and intermediate-1 IPSS risk. Total white blood cell and neutrofils counts were 8.3 3 10/L and 4.8 3 10/L, retrospectively; hemoglobin and platelet counts were 104 g/L and 88 3 10/L, respectively. The development of MDS secondary to chemotherapy or radiotherapy is a well known and rather common phenomenon, while the coexistence of de novo MDS and non-Hodgkin lymphomas (NHL) prior to any exposure to chemo-radiotherapy is rare [2]; even if some case reports described the simultaneous occurrence of MDS and NHL, the real incidence of these coexisting diseases has not been established yet [3]. DLBCL is an aggressive disorder that represents nearly 40% of all NHL and can occur with a wide range of clinical presentations [4]. In consideration of the higher incidence of DLBCL in advanced age, it is not unusual that patients with DLBCL present with significant comorbidities, including other oncological diseases; for these cases, treatment should be tailored with a curative intent to the individual patient, unless comorbidities prevent a full therapeutic approach. Concomitant cytopenia is a significant consideration in individualizing the treatment of DLBCL. In particular, the coexistence of a primary MDS negatively interferes with the outcome of lymphoproliferative disease, worsening, in general, the patient’s clinical status and limiting the possibility of a full therapeutic approach [3,5]. In particular, the hematological toxicity of several cytotoxic agents indicated for lymphoma as alkilators or antracyclines may produce prolonged cytopenias and potentially favor leukemic progression; for this reason, a careful evaluation of the treatment choice for patients in whom there is the coexistence of MDS and NHL is necessary [3,5]. The patient was started on standard R-CHOP chemoimmunotherapy program (Rituximab, Vincristine, Adriamicin, Cyclophosphamide, and Prednisone) every 21 days for six cycles, followed by two further Rituximab administrations; given the coexistence of MDS, the dosage of Doxorubicin and Cyclophosphamide was reduced to 50% of the total dose. The patient’s treatment compliance was fairly good and the therapy was administrated as originally planned. The hematological toxicity experienced during the therapy was moderate; in particular, we observed grade 3 anemia only after course 3, while grade 3 neutropenia and grade 4 thrombocytopenia were observed after each R-CHOP course. The patient received 3–6 administrations of granulocyte colony-stimulating factor (G-CSF), for every cycle except the first one, and a total of three red blood cell transfusions. No infectious complication or episode of neutropenic fever occurred. Restaging after the end of R-CHOP therapy documented a complete remission (CR) status of the lymphoma (according to Cheson 2007 [6]); the bone marrow re-evaluation and, in particular, the percentage of myeloid blasts, were comparable to that observed at baseline. After 11 months of follow-up, the clinical status of the patient remains unchanged for DLBCL and MDS.